Bristol-Myers Squibb Company (BMY)
Health Care12 articles
Price chart
Why is BMY moving today?
+0.1%BMY is +0.1% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of just now
Bristol-Myers Squibb Company (BMY) overview
Bristol Myers Squibb is a major pharmaceutical company focused on oncology and immunology.
BMY is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Bristol-Myers Squibb Company trades on the NYSE under the ticker symbol BMY. The most recent market data puts the share price at about $60.65. That is up 0.13% on the session. At that price the company is worth roughly $123.89B.
Over the past 52 weeks, BMY has traded between $42.52 and $68.64. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 13.4. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. BMY also pays a dividend. It yields around 4.16% at the current price.
Key statistics
Source: Yahoo Finance - quote as of just now
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BMY
BMY is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each BMY story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. BMY is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves BMY
- Earnings. BMY reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from BMY.
- Sector news. Health Care stocks often move together, so a rival's news can move BMY too.
- Index weight. BMY is big enough to move the S&P 500 on its own.
Market Mood
Latest BMY news
Bristol Myers Squibb (BMY) Requires $252,000 for $10,000 Income
To generate $10,000 annually from Bristol Myers Squibb (BMY), an investor would need approximately 3,968 shares and a capital investment of about $252,000 at the current dividend yield of 3.94%. Eliquis, one of BMY's key drugs, may face a revenue decline between $1.5 billion and $2 billion in 2027 due to a patent expiration in April 2028. Meanwhile, BMY's Growth Portfolio now accounts for nearly 60% of its revenue, which grew 14%. With the stock having increased over 40% in the past year, investors should reassess their position as dividends could be impacted by future earnings changes.
Read More: Bristol Myers Squibb (BMY) Requires $252,000 for $10,000 Income
AstraZeneca and Bristol Myers Squibb Discuss Potential Merger
AstraZeneca and Bristol Myers Squibb have reportedly discussed a merger, marking significant interest in major pharmaceutical alliances. The conversation comes as rising interest rates affect market dynamics. This potential merger could reshape the pharmaceutical industry landscape. For investors, the implications of such a merger might lead to changes in stock performance and market strategies surrounding these companies' shares.
Read More: AstraZeneca and Bristol Myers Squibb Discuss Potential Merger
Wall St Futures Rise 1.12% on Mideast Deal Hopes and Healthcare
U.S. stock index futures increased, with Dow E-minis up 589 points (1.12%) as tensions in the Middle East eased, causing Brent crude prices to drop by 6.6%. Bristol Myers Squibb and AstraZeneca are reportedly engaging in preliminary merger talks, potentially creating a $400 billion drugmaker. The yield on the two-year Treasury note also fell by 5.4 basis points. Investors are watching upcoming earnings reports, particularly from AI-related companies, following recent reports from Amazon and Microsoft. This is significant for investors as market sentiment may improve with potential consolidation in healthcare and clearer earnings guidance.
Read More: Wall St Futures Rise 1.12% on Mideast Deal Hopes and Healthcare
Stocks Making Moves Premarket: Alibaba, Bristol-Myers, eBay
Several stocks showed significant movements in premarket trading, including Alibaba, Bristol-Myers Squibb, and eBay. These companies are part of a group making headlines for varying reasons, including earnings reports and market reactions. However, the article does not provide specific numbers, percentage changes, or analyst comments regarding their premarket performances. This trend is essential for investors looking to gauge market sentiment and make informed decisions about their investments.
Read More: Stocks Making Moves Premarket: Alibaba, Bristol-Myers, eBay
AstraZeneca to Discuss $400 Billion Merger with Bristol Myers Squibb
AstraZeneca is in talks with Bristol Myers Squibb regarding a possible merger valued at approximately $400 billion, according to the Financial Times. This potential deal could lead to one of the largest mergers in history within the pharmaceutical industry. Bristol Myers Squibb has had a proactive acquisition strategy, having bought seven companies since October 2007. The outcome of these discussions is still uncertain, but the combined company would have a significant presence in cancer treatment, impacting market dynamics for healthcare investors.
Read More: AstraZeneca to Discuss $400 Billion Merger with Bristol Myers Squibb
BMY vs JNJ: Healthcare Revenue Comparison for 2025
In fiscal 2025, Bristol Myers Squibb (BMY) reported revenue of nearly $48.2 billion, a decrease of approximately 0.2% from the previous year, with a net income of roughly $7.1 billion and a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved approximately $94.2 billion in revenue, reflecting an increase of nearly 6% year-over-year, accompanied by a net income of around $26.8 billion and a net margin of 28.5%. BMY's balance sheet showed a debt-to-equity ratio of 2.6 and a current ratio of 1.3, while its free cash flow reached nearly $12.8 billion. These figures underscore the differing financial health and revenue growth trajectories of these two healthcare companies.
Read More: BMY vs JNJ: Healthcare Revenue Comparison for 2025
BMY and JNJ Financials: 2025 Revenue Numbers Declared
For FY 2025, Bristol Myers Squibb (BMY) reported revenue of approximately $48.2 billion, reflecting a slight decline of 0.2% year-over-year, while net income was $7.1 billion, yielding a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved revenue of about $94.2 billion, marking a 6.0% increase, with a net income of nearly $26.8 billion and a net margin of 28.5%. BMY's debt-to-equity ratio stood at 2.6x, while JNJ's was 0.6x, indicating differing financial leverage. Their performance could influence investor strategies given the contrasting growth potential and stability they provide.
Read More: BMY and JNJ Financials: 2025 Revenue Numbers Declared
SCHD Fund Achieves 20% Return with $71.6B Assets and 3.3% Yield
The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a year-to-date price return of 20% and currently yields approximately 3.3%. The fund has $71.6 billion in assets and a low expense ratio of 0.06%. Its top holdings include Bristol Myers Squibb, Lockheed Martin, and Chevron, all recognized as Dividend Aristocrats with strong free cash flow. The balanced weighting of positions helps mitigate risks, reinforcing distribution safety despite recent company-specific challenges.
Read More: SCHD Fund Achieves 20% Return with $71.6B Assets and 3.3% Yield
Bristol Myers (BMY) Uses Claude AI for Drug Discovery Initiative
Bristol Myers Squibb (BMY) announced its partnership with Anthropic to implement the Claude AI model in its drug discovery process. This collaboration aims to enhance efficiency and reduce timelines associated with drug development. The deployment of AI technology exemplifies BMY's commitment to innovation within the pharmaceutical sector. As companies increasingly adopt AI tools, the market could see shifts in research and development dynamics, potentially impacting stock performance.
Read More: Bristol Myers (BMY) Uses Claude AI for Drug Discovery Initiative
Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Bristol Myers Squibb (BMY) reported Q1 adjusted earnings of $1.58 per share, exceeding analysts' expectations of $1.42, with revenue of $11.49 billion also surpassing the forecast of $10.9 billion. Eliquis, partnered with Pfizer, generated $4.14 billion in sales, an increase of 16% year-over-year. Sales from the growth portfolio rose 12% to $6.23 billion, while sales of Opdivo fell 5% to $2.15 billion. The company reaffirmed its 2026 revenue outlook of $46.0 billion to $47.5 billion and adjusted earnings of $6.05 to $6.35 per share.
Read More: Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
Bristol-Myers Squibb Company (BMY) ranks 5th among the best defensive stocks and is recognized for low volatility and high yield. The stock features a beta that is approximately 73% less volatile than the S&P 500. Recent updates include a quarterly dividend of $0.63 per share and a cash payout ratio of about 35%. In the recent quarter, growth products like Camzyos and Sotyktu saw a 10% increase, which strengthens BMY's long-term revenue outlook despite some earnings challenges.
Read More: Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
BMY Stock Rating Reiterated at Buy by Guggenheim
Guggenheim has reiterated its 'Buy' rating on Bristol-Myers Squibb (BMY). This endorsement could signal ongoing confidence in the company's stock performance amid its recent market activities. As institutional recommendations often influence investor sentiment, this reaffirmation may encourage additional interest from shareholders. It reflects a strategic outlook towards BMY amidst a competitive biotechnology sector.
Read More: BMY Stock Rating Reiterated at Buy by GuggenheimMore Health Care stocks
Frequently asked questions
Is Bristol-Myers Squibb Company in the S&P 500?
Yes. Bristol-Myers Squibb Company trades as BMY and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is BMY in?
BMY sits in the Health Care sector of the S&P 500.
Where can I find the latest BMY news?
Right here. This page collects recent BMY news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Bristol-Myers Squibb Company's stock price?
BMY last traded at about $60.65. Prices move all through the session, so this is the latest quote rather than a live one.
What is Bristol-Myers Squibb Company's market cap?
BMY is worth roughly $123.89B. Market cap is the share price times the number of shares outstanding.
What is BMY's P/E ratio?
BMY trades at a trailing P/E ratio of about 13.4. The ratio compares the share price with earnings per share over the past year.